When the anti-TNF Ab afelimomab was studied in a phase-III trial including sepsis patients using stratification, only patients with IL-6 levels > 1000 pg/mL had a reduced 28-day mortality (44% vs. 48%, n = 998) [18]. Here, TNF is linked to Sepsis.